Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.

Abstract: Systems, methods, and computer readable media for determining cognitive impairment (CI) in patients are provided herein. Various regional structural-functional parameters of the retina can serve as biomarkers for the detection of CI. The method can include forming a database including a quantification of retinal structure and retinal function of a plurality of eyes associated with a plurality of patients, providing a baseline cognitive impairment (CI) reference. The method can include determining a measure of functionality of neurons in the retina based on an electroretinogram (ERG) of a patient. The method can include determining a structural measure of the first retina based on a generalized dimension spectrum and singularity spectrum of the skeletonized retinal image, and a lacunarity parameter of the skeletonized retinal image. The method can include determining a level of cognitive impairment based on the structural and functional measures.

Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions.

Abstract: A device and method for aspirating graft tissue and delivering the graft tissue to a target delivery site (for example, when performing Descemet's membrane endothelial keratoplasty). In one embodiment, an injector comprises a cylinder and a plunger at least partially located within the cylinder, the plunger being rotatably advanceable and retractable within the cylinder. In one aspect of the embodiment, rotating the plunger in a first direction within the cylinder controllably aspirates a graft tissue into the injector and rotating the plunger in a second direction opposite the first direction controllably ejects the graft tissue from the injector.

Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.

Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.

Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.

Abstract: In certain embodiments, double-vision-related vision defects determinations or modifications may be facilitated. In some embodiments, a stimulus may be to be presented at a first time at a position on a first display for a deviating eye of a user (e.g., without a stimulus being presented on a second display of for a reference eye of the user) to cause the deviating eye to fixate on the position on the first display. A deviation measurement for the deviating eye may be determined based on an amount of movement of the deviating eye occurring upon the presentation on the first display for the deviating eye at the first time. In some embodiments, a modification profile associated with the user may be determined based on the deviation measurement, where the modification profile includes one or more modification parameters to be applied to modify an image for the user.

Abstract: Compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for inflammasome-related diseases or disorders such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammaging or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with an inflammasome-related disease or disorder such as multiple sclerosis, stroke, mild cognitive impairment, Alzheimer's disease, age-related macular degeneration, NASH, inflammaging or traumatic brain injury are also described.

Abstract: In certain embodiments, double-vision-related vision defects determinations or modifications may be facilitated. In some embodiments, a stimulus may be to be presented at a first time at a position on a first display for a deviating eye of a user (e.g., without a stimulus being presented on a second display of for a reference eye of the user) to cause the deviating eye to fixate on the position on the first display. A deviation measurement for the deviating eye may be determined based on an amount of movement of the deviating eye occurring upon the presentation on the first display for the deviating eye at the first time. In some embodiments, a modification profile associated with the user may be determined based on the deviation measurement, where the modification profile includes one or more modification parameters to be applied to modify an image for the user.

Abstract: Systems and methods for assessing, monitoring, or theranosing a condition or disorder based on a comparison of limb stability for one or more limbs of a subject from a baseline. The method includes placing two or more inertial measurement sensors on the limbs of the subject, acquiring baseline limb excursion data from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity by tracking the relative displacement of the respective two or more inertial measurement sensors; acquiring post-injury limb excursion data after an injury from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity; and determining the activity clearance index as a function of a comparison of the baseline limb excursion data compared to the post-injury limb excursion data.

Abstract: The present invention provides an expression vector, host cells, methods and kits for the treatment or prevention of a flavivirus infection in a subject.

Abstract: In some embodiments, initial feedback indicating threshold characteristics (under which a user sees initial stimuli presented on a user interface) may be provided to a prediction model, and a set of predicted characteristics (for a set of locations of the user interface) and a set of confidence scores associated with the set of locations may be obtained via the prediction model. Based on the set of confidence scores, one or more locations may be selected to be tested during a visual test presentation. As an example, the locations may be selected over one or more other locations of the set of locations based on the set of confidence scores. Based on predicted characteristics associated with the selected locations, stimuli may be presented at the selected locations during the visual test presentation. Visual defect information for the user may be generated based on feedback from the visual test presentation.

Abstract: In some embodiments, initial feedback indicating threshold characteristics (under which a user sees initial stimuli presented on a user interface) may be provided to a prediction model, and a set of predicted characteristics (for a set of locations of the user interface) and a set of confidence scores associated with the set of locations may be obtained via the prediction model. Based on the set of confidence scores, one or more locations may be selected to be tested during a visual test presentation. As an example, the locations may be selected over one or more other locations of the set of locations based on the set of confidence scores. Based on predicted characteristics associated with the selected locations, stimuli may be presented at the selected locations during the visual test presentation. Visual defect information for the user may be generated based on feedback from the visual test presentation.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising Interleukin-2 (IL-2) or a functional variant or fragment thereof; and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL-2R?) or a functional variant or fragment thereof, and wherein the fusion protein has IL-2 activity. Various methods are provided for modulating the immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the IL-2/IL-2R? fusion protein disclosed herein.

Abstract: Molecular signatures that function as very sensitive diagnostic biomarker for myocarditis, heart disease and disorders thereof, are identified.

Abstract: Systems and devices for temporarily disabling an assailant or other target using disabling flashes of light from a light-emitting device. A tactical lighting system also includes protective eyewear that is paired with the light-emitting device and configured to shutter in synchronization with the pattern of disabling light flashes to protect the wearer's eyes while disabling an assailant or other target.

Abstract: Quantification of symmetry and repeatability in limb motion for treating abnormal motion patterns. In the context of gait analysis, gait data may be acquired as signals from inertial sensors (e.g., gryoscopes). Each signal represents an angular velocity of a lower limb segment of a subject during ambulation. Each signal may be segmented into stride signals, and a gait metric may be calculated based on the stride signals. The gait metric may comprise a symmetry metric that represents a similarity of the stride signals across two signals acquired for at least one pair of contralateral limb segments. Additionally or alternatively, the gait metric may comprise a repeatability metric that represents a similarity of the stride signals within a signal. In other embodiments, other types of sensors may be used and/or motion data may be acquired and metrics calculated for other types of motions and/or for upper limb segments.

Abstract: A plasmonic photoconductor sensing platform is provided. The plasmonic photoconductor sensing platform includes an insulating substrate; a semiconducting film placed on top of the insulating substrate; two metal contacts placed at least in part on the semiconducting film to enforce an electric field; a plurality of plasmonic nanostructures deposited on the semiconducting film and physically separated from metal contacts; an insulating layer, the insulating electrically isolating the plasmonic nanostructures from semiconductor; at least one energy source; and at least one microfluidic channel disposed on the insulating layer.